001468237 000__ 05781cam\\22006137i\4500
001468237 001__ 1468237
001468237 003__ OCoLC
001468237 005__ 20230707003401.0
001468237 006__ m\\\\\o\\d\\\\\\\\
001468237 007__ cr\cn\nnnunnun
001468237 008__ 230526s2023\\\\sz\a\\\\o\\\\\000\0\eng\d
001468237 019__ $$a1379445505$$a1379478733$$a1379488561
001468237 020__ $$a9783031205217$$q(electronic bk.)
001468237 020__ $$a3031205219$$q(electronic bk.)
001468237 020__ $$z3031205200
001468237 020__ $$z9783031205200
001468237 0247_ $$a10.1007/978-3-031-20521-7$$2doi
001468237 035__ $$aSP(OCoLC)1380366698
001468237 040__ $$aGW5XE$$beng$$erda$$epn$$cGW5XE$$dYDX
001468237 049__ $$aISEA
001468237 050_4 $$aRC111
001468237 08204 $$a616.9/0461$$223/eng/20230526
001468237 24500 $$aInfectious diseases drug delivery systems /$$cRanjita Shegokar, Yashwant Pathak, editors.
001468237 264_1 $$aCham, Switzerland :$$bSpringer,$$c2023.
001468237 300__ $$a1 online resource (350 pages) :$$billustrations (black and white, and color).
001468237 336__ $$atext$$btxt$$2rdacontent
001468237 337__ $$acomputer$$bc$$2rdamedia
001468237 338__ $$aonline resource$$bcr$$2rdacarrier
001468237 5050_ $$aNew drugs in synthesis research for Malaria -- New drugs in synthesis research for TB -- New drugs in synthesis viral -- Nanotechnology in Malaria diagnosis -- Nanotechnology in TB diagnosis -- Nanotechnology based vaccination Malaria -- Nanotechnology based vaccination TB -- Disease models in Malaria research -- Disease models in TB research -- Disease models in Viral research -- Viral diseases- cellular understanding of disease : Vaccine development -- Pneumonia- infection -- bacterial pnuemonia -- Lipid based DDS in pneumonia -- hepatitis -- Recent Developments in the Treatment of Bacterial Meningitis -- Bacterial Urinary Tract Infections -- E.coli.
001468237 506__ $$aAccess limited to authorized users.
001468237 520__ $$aThe disability-adjusted life year (DALY) is a generic measure of health effect that can be used in cost-effectiveness analysis as an alternative to the quality-adjusted life year (QALY). Infectious diseases are one of the major to cause significant losses of DALY and QALY. Human infectious diseases are disorders that are triggered by the micro-organisms such as bacteria, fungi, viruses, or parasites. The majority of such diseases are contagious and create a public health menace. There are several reasons why infectious diseases are deadly diseases, and one of the primary reasons is the drug resistance developed over time. Drug resistance-associated mutations are linked to increasing drug efflux, modifications of the drugs, or their targets. Every year, new drugs are being approved by FDA to treat infectious diseases. Nonetheless, the infectious diseases will undoubtedly persist as permanent and main threats to humanity for now and in the future. A total of four books are covered under the series of Infectious drug diseases. - Malarial drug delivery systems - Tubercular drug delivery systems - Viral drug delivery systems - Infectious disease drug delivery systems Infectious diseases are the worlds greatest killers that present one of the most significant health and security challenges. Humans have lived with emerging and re-emerging pathogens since before the documented history of civilization. The only determining fact today is - If the situation is worse or better than in past. The answer is probably worse, may be due significant increase in human population, increased cross-continent mobility, imbalanced (stressed) life style, irregular food habits leading to compromised innate immunity and over or under practiced hygiene routine. When the incidence of such a disease in people increases over 20 years or threatens to increase, it is called an emerging disease, and a growing number have made watch lists and headlines in nearly every country -like highly pathogenic H5N1 avian influenza, severe acute respiratory syndrome (SARS), Ebola virus, food- and waterborne illnesses, and a range of antimicrobial-resistant bacterial diseases TB. This book addresses current and new therapy developments in treating such infectious diseases, updates on finding new drugs, identification of innovative diagnostic methods, understanding of disease research models and clinical trials performances of new treatment modalities. Audiences from a broad range of groups, from researchers, academicians, and public health bodies to regulatory experts, can benefit from the compiled information to learn more about patient needs and current research advances in the field of infectious diseases and related research.
001468237 588__ $$aDescription based on print version record.
001468237 650_0 $$aCommunicable diseases$$xChemotherapy.
001468237 650_0 $$aDrug delivery systems.
001468237 650_0 $$aDisability evaluation.
001468237 650_0 $$aQuality of life.
001468237 655_0 $$aElectronic books.
001468237 7001_ $$aShegokar, Ranjita,$$eeditor.
001468237 7001_ $$aPathak, Yashwant,$$eeditor.
001468237 77608 $$iPrint version:$$tINFECTIOUS DISEASES DRUG DELIVERY SYSTEMS.$$d[Place of publication not identified] : SPRINGER INTERNATIONAL PU, 2023$$z3031205200$$w(OCoLC)1346536954
001468237 852__ $$bebk
001468237 85640 $$3Springer Nature$$uhttps://univsouthin.idm.oclc.org/login?url=https://link.springer.com/10.1007/978-3-031-20521-7$$zOnline Access$$91397441.1
001468237 909CO $$ooai:library.usi.edu:1468237$$pGLOBAL_SET
001468237 980__ $$aBIB
001468237 980__ $$aEBOOK
001468237 982__ $$aEbook
001468237 983__ $$aOnline
001468237 994__ $$a92$$bISE